(Q36284121)

English

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

Tohru Funahashi

11

object named as

Tohru Funahashi

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Yuya Fujishima

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Norikazu Maeda

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Kana Inoue

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Susumu Kashine

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Hitoshi Nishizawa

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ayumu Hirata

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Junji Kozawa

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Tetsuyuki Yasuda

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Kohei Okita

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Akihisa Imagawa

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Iichiro Shimomura

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

14 September 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Cardiovascular Diabetology

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

107

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

https://scigraph.springernature.com/pub.10.1186/1475-2840-11-107

0 references

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Association between body-mass index and risk of death in more than 1 million Asians

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

30 September 2017

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-107

21 January 2018

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3459720

22 September 2018

Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22973968

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1475-2840-11-107

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36284121&oldid=1623342698"